
Biohaven Ltd.
BHVNNYSEHealthcareBiotechnology
Regular session
$13.755
−$0.095 · -0.69%
BHVN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
65
Gaining
Sentiment
44
Mixed
Risk resilience
32
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBiohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Vladimir Coric
- Listed since
- Sep 23, 2022
- Employees
- 274
Market position
Day range
Current $13.755
52-week range
Current $13.755
- Open
- $13.95
- Previous close
- $13.85
- Volume
- 196.73K
- 0.08× average
- Average volume
- 2.57M
- Average daily volume
- Market cap
- 2.07B USD
- Beta
- 3.16
- Market reference 1
- 50-day average
- $14.4514
- -4.82% below average
- 200-day average
- $11.3798
- +20.87% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.27B USD
- P/E (TTM)
- -2.98×
- P/B (TTM)
- 170.46×
- P/S (TTM)
- 0×
- EV / EBITDA
- -1.75×
- Earnings yield
- -60.80%
- Free cash flow yield
- -50.21%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -1418.85%
- Return on assets
- -163.66%
- Return on invested capital
- -218.41%
Financial health
- Debt / equity
- 24.3×
- Current ratio
- 3.18×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 4.14M USD | — | — | — | — |
| Gross profit | −4.14M USD | — | — | — | — |
| Research and development | 635.07M USD | 795.87M USD | 373.28M USD | 437.07M USD | 181.49M USD |
| Selling, general, and administrative | 106.17M USD | 89.24M USD | 62.77M USD | 130.86M USD | 37.41M USD |
| Operating expenses | 741.24M USD | 885.11M USD | 436.05M USD | 567.93M USD | 218.9M USD |
| Interest income | 14.59M USD | 21.33M USD | 17.73M USD | — | — |
| Depreciation and amortization | 9.92M USD | 7.86M USD | 6.91M USD | 1.39M USD | 1.39M USD |
| Operating income | −745.38M USD | −885.11M USD | −436.05M USD | −567.93M USD | −218.9M USD |
| Net income | −738.82M USD | −846.42M USD | −408.17M USD | −570.28M USD | −213.8M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 18%
- 2 beats, 7 misses, 2 met estimates
- Average EPS surprise
- -22.01%
- 11 comparable reports
- Latest EPS result
- -0.91
- Estimate -0.76 · Miss by 19.58%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$13.75
0.04% downsideETFs holding BHVN
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI53.72M0.47%11.39B USD0.35%$162.5-1.95%
iShares Russell 2000 ETFIWM47.1M0.06%81.62B USD0.19%$298.57-0.46%
Vanguard Extended Market ETFVXF20.13M0.02%93.7B USD0.05%$243.76-0.72%
iShares Russell 2000 Growth ETFIWO17.05M0.11%15.16B USD0.24%$383.11-1.10%
iShares Biotechnology ETFIBB12.9M0.12%10.75B USD0.44%$210.64-1.37%
Vanguard Russell 2000 ETFVTWO10.11M0.06%17.4B USD0.06%$120.73-0.43%
Schwab U.S. Small-Cap ETFSCHA8.56M0.04%23.1B USD0.03%$34.445-1.12%
Simplify Health Care ETFPINK8.01M2.10%380.8M USD0.51%$40.10-0.27%
State Street SPDR S&P Biotech ETFXBI- Market value
- 53.72M
- Weight
- 0.47%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $162.5-1.95%
iShares Russell 2000 ETFIWM- Market value
- 47.1M
- Weight
- 0.06%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $298.57-0.46%
Vanguard Extended Market ETFVXF- Market value
- 20.13M
- Weight
- 0.02%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.76-0.72%
iShares Russell 2000 Growth ETFIWO- Market value
- 17.05M
- Weight
- 0.11%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $383.11-1.10%
iShares Biotechnology ETFIBB- Market value
- 12.9M
- Weight
- 0.12%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $210.64-1.37%
Vanguard Russell 2000 ETFVTWO- Market value
- 10.11M
- Weight
- 0.06%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $120.73-0.43%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 8.56M
- Weight
- 0.04%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.445-1.12%
Simplify Health Care ETFPINK- Market value
- 8.01M
- Weight
- 2.10%
- AUM
- 380.8M USD
- Expense ratio
- 0.51%
- Price / 1D
- $40.10-0.27%
Continue in GoAI
Research BHVNresearch.disclaimer